These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 2988391

  • 1. Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid.
    Glover DJ, Shaw L, Glick JH, Slatopolsky E, Weiler C, Attie M, Goldfarb S.
    Ann Intern Med; 1985 Jul; 103(1):55-7. PubMed ID: 2988391
    [Abstract] [Full Text] [Related]

  • 2. Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma.
    Hirschel-Scholz S, Jung A, Fischer JA, Trechsel U, Bonjour JP.
    Clin Endocrinol (Oxf); 1985 Sep; 23(3):313-8. PubMed ID: 3000652
    [Abstract] [Full Text] [Related]

  • 3. Hypocalcaemic effect of WR-2721, S-2 (3-aminopropylamino) ethyl-phosphorothioic acid in an anuric haemodialysis patient.
    Zingraff J, Bourdeau A, Clair F, Kindermans C, Buisson C, Manganella G, Sachs C, Drüeke T.
    Nephrol Dial Transplant; 1987 Sep; 2(1):48-52. PubMed ID: 3037448
    [Abstract] [Full Text] [Related]

  • 4. S-2-(3-Aminopropylamino)ethyl phosphorothioic acid (WR-2721) in primary hyperparathyroidism.
    Morita M, Higashi K, Tajiri J, Sato T.
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):961. PubMed ID: 2998254
    [No Abstract] [Full Text] [Related]

  • 5. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
    Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM.
    J Clin Oncol; 1986 Apr; 4(4):584-8. PubMed ID: 3007686
    [Abstract] [Full Text] [Related]

  • 6. In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.
    Weiss J, Walker ST, Fallon M, Goldfarb S.
    J Pharmacol Exp Ther; 1986 Sep; 238(3):969-73. PubMed ID: 3018229
    [Abstract] [Full Text] [Related]

  • 7. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells.
    Attie MF, Fallon MD, Spar B, Wolf JS, Slatopolsky E, Goldfarb S.
    J Clin Invest; 1985 Apr; 75(4):1191-7. PubMed ID: 2985652
    [Abstract] [Full Text] [Related]

  • 8. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
    Hirschel-Scholz S, Caverzasio J, Rizzoli R, Bonjour JP.
    J Clin Invest; 1986 Jul; 78(1):319-22. PubMed ID: 3013941
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of the hypocalcemic agent WR-2721 and its acute and chronic application in eu- and hyperparathyroidism.
    Hirschel-Scholz S, Caverzasio J, Bonjour JP.
    Adv Exp Med Biol; 1986 Jul; 208():367-70. PubMed ID: 3031946
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Parathyroid adenoma with conflicting parathyroid hormone levels.
    Goldman MH, Suresh A.
    N J Med; 1990 Oct; 87(10):815-7. PubMed ID: 2234522
    [Abstract] [Full Text] [Related]

  • 13. Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration.
    Mangold DJ, Miller MA, Huelle BK, Sanchez-Barona DO, Swynnerton NF, Fleckenstein L, Ludden TM.
    Drug Metab Dispos; 1989 Oct; 17(3):304-10. PubMed ID: 2568913
    [Abstract] [Full Text] [Related]

  • 14. An improved HPLC assay for S-2-(3-aminopropylamino)ethyl phosphorothioate (WR-2721) in plasma.
    Swynnerton NF, McGovern EP, Niño JA, Mangold DJ.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1521-4. PubMed ID: 6090354
    [Abstract] [Full Text] [Related]

  • 15. [HIV-positive patient with hypercalcemia and normal PTH].
    Pérez-Rodríguez MT, Ocampo A, Longueira R, Martínez-Vázquez C.
    Enferm Infecc Microbiol Clin; 2009 Sep; 27(7):430-2. PubMed ID: 19406525
    [No Abstract] [Full Text] [Related]

  • 16. Management of hypercalcemia in relation to pathophysiology.
    Bonjour JP, Rizzoli R, Hirschel-Scholz S, Caverzasio J.
    Bone; 1987 Sep; 8 Suppl 1():S29-33. PubMed ID: 2825740
    [Abstract] [Full Text] [Related]

  • 17. Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells.
    Issels RD, Nagele A.
    Cancer Res; 1989 Apr 15; 49(8):2082-6. PubMed ID: 2539252
    [Abstract] [Full Text] [Related]

  • 18. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent).
    Glover D, Riley L, Carmichael K, Spar B, Glick J, Kligerman MM, Agus ZS, Slatopolsky E, Attie M, Goldfarb S.
    N Engl J Med; 1983 Nov 10; 309(19):1137-41. PubMed ID: 6312315
    [Abstract] [Full Text] [Related]

  • 19. Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma.
    Warrell RP, Issacs M, Alcock NW, Bockman RS.
    Ann Intern Med; 1987 Nov 10; 107(5):683-6. PubMed ID: 2821862
    [Abstract] [Full Text] [Related]

  • 20. Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma.
    Vega EM, Mautalen CA.
    Medicina (B Aires); 1991 Nov 10; 51(2):106-10. PubMed ID: 1820495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.